Although most of the media spotlight has fallen on the development of vaccines, the development of improved treatments for those who have been infected by the Covid-19 virus is a separate story, and one no less fascinating. A new pill known as Molnupiravir shows great promise. It was invented by scientists at Emory University, in Georgia, then licensed by Ridgeback Biotherapeutics in a strategic partnership with Merck.
At a time when much of the treatment of sufferers with the disease is a matter of treating symptoms, a simple oral anti-viral treatment, one that takes the offensive rather than playing defense and waiting out the invader, fills a great need.
Molnupiravit is designed as part of a five-day, at-home treatment. Scientists involved in the testing have said it could be on the market within four or five months.
In Pill Form:
According to a recent statement from Dr. Roy Baynes, “We continue to make progress in our Phase 2/3 clinical programs evaluating molnupiravir in both outpatient and hospital settings and plan to provide updates when appropriate.” Baynes is the senior vice president and head of global clinical development, chief medical officer, Merck Research Laboratories.